Optas LLC Trims Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Optas LLC reduced its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 11.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,443 shares of the company's stock after selling 453 shares during the quarter. Optas LLC's holdings in Eli Lilly and Company were worth $2,844,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock worth $12,278,292,000 after purchasing an additional 14,852,076 shares during the last quarter. Norges Bank purchased a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $8,407,908,000. Proficio Capital Partners LLC lifted its holdings in shares of Eli Lilly and Company by 100,387.1% in the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock valued at $4,016,110,000 after buying an additional 5,197,038 shares during the period. Wellington Management Group LLP boosted its stake in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after buying an additional 2,012,129 shares during the last quarter. Finally, Capital International Investors grew its holdings in Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock worth $6,740,272,000 after acquiring an additional 1,645,222 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.8%

LLY traded up $6.53 during trading on Friday, hitting $818.56. The company's stock had a trading volume of 2,753,537 shares, compared to its average volume of 3,658,306. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The stock has a market cap of $775.78 billion, a PE ratio of 69.90, a PEG ratio of 1.40 and a beta of 0.41. The firm's 50 day moving average price is $775.43 and its 200-day moving average price is $801.59. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The company had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Eli Lilly and Company's revenue was up 45.2% on a year-over-year basis. During the same period in the prior year, the business posted $2.58 earnings per share. On average, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.73%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Analyst Ratings Changes

LLY has been the topic of a number of analyst reports. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their target price for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Guggenheim restated a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. Finally, UBS Group reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.